Clinical trial
An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous…
NCT00402467 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00402467 |
|---|---|
| Title | An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Venous Thromboembolism |
| Intervention type | Drug |
| Interventions | Rivaroxaban (BAY59-7939), Rivaroxaban, (BAY59-7939), Enoxaparine |
| Enrollment | 613 |
| Start date | Feb 1, 2004 |
| Primary completion | Nov 1, 2004 |
| Completion | Nov 1, 2004 |
| First posted | Nov 22, 2006 |
| Last update posted | Dec 23, 2014 |
| Countries | Canada, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: